Only first 10,000 results will be saved in the file.
No item is selected. Use checkboxes to select search results.
Displaying 1-1 of 1 results.
{{ selectedCountPage }} items selected on this page,{{ selectedCountPage }} item selected on this page,{{ selectedCountTotal }} item in total{{ selectedCountTotal }} items in total
The objective of this study is to assess the efficacy of Riluzole in the treatment of autism. Fifty children between the ages 3 and 12 years with a DSM IV clinical diagnosis of autistic disorder and who will be outpatients from a specialty clinic for children will be recruited. The children should present with a chief complaint of severely disruptive symptoms related to autistic disorder. Patients will be randomly allocated into Riluzole (50-100 mg/day ) + Risperidone (1-3mg/day) or Placebo + Risperidone (1-3 mg/day) for a 10-week, double-blind, placebo-controlled study. Patients will be assessed at baseline and after 5,10 weeks of starting medication. The primary outcome measure is the Aberrant Behavior Checklist-Community (ABC-C) Rating Scale and CGI